Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
US8455249B2 · kind B2 · utility
4Cited by
21References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 30, 2010 |
| Grant date | Jun 4, 2013 |
| Priority date | — |
| Expiry date | Apr 30, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/732
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 μg/mL is 30% or more.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.